Archive · 6 Oct 2026
Lord’s Mark Secures MHRA Registration for UK Diagnostics Expansion
Lord’s Mark Industries has registered a group of diagnostic products with the UK’s medical regulator.
These products include machines that test blood and other equipment used in laboratories.
The registration is an important step before the products can be sold in Great Britain.
The company plans to start selling them in the UK in December 2026.
It also plans to open a pathology laboratory in January 2027.
Earlier, the company registered its Renalyx haemodialysis system with the same regulator.
Together, these plans are meant to help the company offer more healthcare products and services in the UK and allied markets.
Lord’s Mark Industries’ in-vitro diagnostic portfolio was registered with the UK’s MHRA on September 24, 2026.
The registration covers haematological cell analysers, clinical chemistry analysers, buffered sample diluents and cleaning agents.
The company plans to begin UK commercial sales of its IVD products in December 2026, about two months ahead of its earlier schedule.
Lord’s Mark Industries plans to start operating a pathology laboratory in January 2027.
The registration follows the company’s MHRA registration for its AI-powered Renalyx haemodialysis system.
- Who
- Lord’s Mark Industries Limited
- What
- Registered its IVD portfolio with the UK’s Medicines and Healthcare products Regulatory Agency.
- When
- The registration is dated September 24, 2026; planned UK sales begin in December 2026, with the pathology laboratory planned for January 2027.
- Where
- The United Kingdom, with the company also pursuing opportunities in UK-allied markets subject to local regulatory requirements.
- Why
- To advance the company’s planned expansion of its diagnostics and healthcare products and services in the UK and allied markets.
- Registration date
- September 24, 2026
- Regulator
- UK Medicines and Healthcare products Regulatory Agency (MHRA)
- Registered portfolio
- In-vitro diagnostic products, including analysers, buffered sample diluents and cleaning agents
- Planned UK sales
- December 2026, approximately two months ahead of the earlier schedule
- Planned pathology laboratory launch
- January 2027
- Earlier registration mentioned
- MHRA registration for the AI-powered Renalyx haemodialysis system, announced in September
- Market requirement
- The article says medical devices, including IVDs, must be registered with MHRA before being placed on the Great Britain market.